# I-Mab

Source: https://onco.cc/companies/i-mab/  
OnCo record `i-mab` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

I-Mab is a biotech, founded in Shanghai and now based in Maryland, whose Claudin 18.2 and 4-1BB bispecific givastomig and CD73 antibody uliledlimab are in trials for stomach and lung cancer.

## Summary

I-Mab develops immuno-oncology biologics and moved its headquarters to Rockville, Maryland after separating from its Chinese operations in 2024. Givastomig (TJ-CD4B), a Claudin 18.2 and 4-1BB bispecific, is in phase 1b/2 trials with nivolumab and chemotherapy in first-line gastric cancer. Uliledlimab (TJ004309) is a differentiated CD73 antibody studied with toripalimab in non-small cell lung cancer. The company also developed lemzoparlimab, a CD47 antibody once licensed to AbbVie.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: I-Mab Biopharma; 天境生物; NASDAQ:IMAB
- Tags: drug-maker
- HQ: Rockville, Maryland
- Type: biotech
- Website: https://www.i-mabbiopharma.com/
- Ticker: NASDAQ:IMAB

## Sources

- Official website: https://www.i-mabbiopharma.com/

## Connected records

- drugs: [Uliledlimab](https://onco.cc/drugs/uliledlimab/)

---
JSON: https://onco.cc/api/v1/entities/i-mab.json